Skip to main content

KYMR Kymera Therapeutics, Inc.

Healthcare

119.39 USD 1D -1.74 -1.44% Close 11/19
Since 2024-12-19 +209.5%

Close 11/19

Open
121.00
High
122.47
Low
117.65
Prev close
121.13
Volume
723.17K
Amplitude
3.98%
P/B
6.4
Revenue YoY (TTM)
+133.7%
52W 63.69 142.92
FinLab Studio

From Kymera Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Kymera Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Kymera Therapeutics, Inc.

Is Kymera Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-11-18

Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey, Quality: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -33.4 N/A
Price / book 6.4 88th percentile · Expensive
Free-cash-flow yield (%) -2.8 36th percentile · Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak ROE, TTM is Average; Operating margin, TTM is Lagging.
ROE, TTM (%) -21.7 25th percentile · Average
Operating margin, TTM (%) -396.1 8th percentile · Lagging
FCF margin, TTM (%) -282.6 9th percentile · Lagging
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 133.7 92th percentile · Top
Diluted EPS growth, TTM YoY (%) 1.1 56th percentile · Good
Momentum Good 240-day return is Top; 60-day return is Good.
60-day return (%) -4.4 63th percentile · Good
240-day return (%) 82.9 96th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 123,900,870.0 89th percentile · Top
60-day annualized volatility (%) 43.2 44th percentile · Good

Kymera Therapeutics, Inc. (KYMR) today

1 quant signals active · As of 2026-11-18

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Kymera Therapeutics, Inc. (KYMR) peers and tracking

Watchlist

This page refreshes daily after the close. Add Kymera Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Kymera Therapeutics, Inc. (KYMR) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 93.2%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

16 historical occurrences (since 2021-02-24)

Average forward return after Top-quintile 6-month momentum

20-day: Win 37.5%, Sample 16, Median -2.4%, Excess +2.1%, Beat mkt rate 43.8%

60-day: Win 64.3%, Sample 14, Median +9.2%, Excess +5.7%, Beat mkt rate 50.0%

120-day: Win 53.8%, Sample 13, Median +6.1%, Excess +1.7%, Beat mkt rate 46.2%

120 days after: historical avg +8.2%

20-day +3.6%
60-day +9.6%
120-day +8.2%
20-day
60-day
120-day
Win
37.5%
64.3%
53.8%
Sample
16
14
13
Median
-2.4%
+9.2%
+6.1%
Excess
+2.1%
+5.7%
+1.7%
Beat mkt rate
43.8%
50.0%
46.2%

Over 13 occurrences, 120-day forward avg gained 8.2%, beat the market by 1.7 pts; win rate 53.8%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 101,417 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.4% positive-return rate, and +2.95 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

10 times historically; 60-day forward avg +7.7%, win rate 55.6%, beating the market by +4.6 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg +4.7%, win rate 60.0%, beating the market by -0.8 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

6 times historically; 60-day forward avg +17.4%, win rate 83.3%, beating the market by +11.3 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.